Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Lunsumio provides high rates of deep and long-lasting responses in third-line and later follicular lymphoma, a disease that typ...
At interim analysis, giredestrant demonstrated a statistically significant and clinically meaningful benefit versus standard-of...
- The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantl...
Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva, an anti-CD20 monoclonal antibody designed for...
New dengue antigen test delivers high clinical sensitivity and specificity, as well as inclusivity for all four dengue virus se...
Gazyva/Gazyvaro versus mycophenolate mofetil shows significantly more children and young adults achieved sustained complete rem...
Outlook for 2025 earnings raisedRoche expects an increase in Group sales in the mid single digit range (CER). Core earnings per...
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated population...
